Does the treatment of primary hyperaldosteronism influence glucose tolerance?

Does the treatment of primary hyperaldosteronism influence glucose tolerance? Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Does the treatment of primary hyperaldosteronism influence glucose tolerance? Abstract Text:

B Strauch,J ,G Sindelka,J Skrha,

Primary hyperaldosteronism (PH) is frequently considered to be a secondary form of diabetes mellitus (DM). In our previous study we attempted to evaluate the prevalence of DM among patients with PH compared to control subjects with essential hypertension (EH). We have noted a relatively high prevalence of DM and impaired glucose tolerance in PH, but the differences between the PH and EH groups did not reach statistical significance. We performed this study to assess whether the effective treatment of PH (surgical and conservative) would improve the glucose tolerance. We have studied 24 patients with PH of the following two subtypes: aldosterone-producing adenoma (APA) treated with adrenalectomy and idiopathic hyperaldosteronism (IHA) treated with spironolactone. No significant changes of glucose levels were found in the 60th and 120th min of the oral glucose tolerance test (OGTT) in the APA group. On the other hand, fasting glucose levels were decreased significantly after adrenalectomy. Plasma glucose levels were significantly increased in the 60th min, but no differences were found in fasting values and in the 120th min in the IHA group. There was a significantly higher incidence of impaired glucose tolerance (36 per cent before, 45 per cent after treatment) and DM (9 per cent, 18 per cent) in the IHA group compared to the APA group (8 per cent, 32 per cent; DM 0 per cent, 0 per cent). In conclusion, the treatment of PH does not improve glucose tolerance. Mild worsening of glucose tolerance after treatment could be explained by an increase of the body mass index. These data, in accordance with our previous study, do not support the idea that PH is a secondary form of diabetes mellitus.

Does the treatment of primary hyperaldosteronism influence glucose tolerance? Publishing Authors By Initials

B Strauch,J ,G Sindelka,J Skrha,

For similar organic chemicals: lactones: spironolactone research abstracts see: organic chemicals: lactones: spironolactone research

PUBMED ID PMID:

MEDLINE DATE:

Does the treatment of primary hyperaldosteronism influence glucose tolerance? Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Physiological research / Academia Scientiarum Bohe

VOLUME: 52

Page Numbers: 503-6

Journal Abbreviation: Physiol Res

ISSN: 0862-8408

DAY: 2

MONTH: 04

YEAR: 2003

Does the treatment of primary hyperaldosteronism influence glucose tolerance? Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9112413

Does the treatment of primary hyperaldosteronism influence glucose tolerance? Keywords Mesh Terms:

KEYWORDS: Spironolactone

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Does the treatment of primary hyperaldosteronism influence glucose tolerance? Information

Substance Name: Spironolactone

Registry Number: 52-01-7

Grant and Affiliation Information for Does the treatment of primary hyperaldosteronism influence glucose tolerance?

AFFILIATION: Third Department of Internal Medicine, First Faculty of Medicine, Charles University, U nemocnice 1, 128 08 Prague 2, Czech Republic. strauch@volny.cz

Country: Czech Republic

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Physiol Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Does the treatment of primary hyperaldosteronism influence glucose tolerance? Related Publications

• Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus?
• DEHYDROEPIANDROSTERONE IN OBESE DIABETICS.
• Does the treatment of primary hyperaldosteronism influence glucose tolerance?
• Impaired insulin action in primary hyperaldosteronism.
• Insulin antibodies.
• The influence of NO synthase inhibitor and free oxygen radicals scavenger--methylene blue--on streptozotocin-induced diabetes in rats.
• The influence of nitric oxide synthase inhibitor L-NAME on bones of male rats with streptozotocin-induced diabetes.
• Vascular calcifications and osteoporosis in diabetes mellitus. X-ray study.
• [Homologous serum jaundice following transfusion of fresh and preserved blood.]